Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: "TRIUMF trial".

Egypt Heart J · 2023 · PMC10409965 · PMID 37552407

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

showed a trendp = 0.069so close (0.05 < p ≤ 0.1)

The composite of all-cause death/HFH showed a trend for fewer events in the Telmisartan compared to Enalapril, with a rate of 8 (18.2%) versus 16 (34%), p = 0.069.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.